Drug intelligence / Profile preview

MVT-601

Development stage: Preclinical
Lead developer: Microvascular Therapeutics
Modality: Drug Delivery Systems
Administration: Intravenous

Overview

MVT-601 is an investigational E-selectin-targeted microbubble contrast agent developed by Microvascular Therapeutics for the molecular imaging and diagnosis of uveitis. The agent consists of lipid-shelled microbubbles functionalized with a ligand that specifically binds to E-selectin (CD62E), an adhesion molecule upregulated on activated vascular endothelial cells during ocular inflammation. In addition to its diagnostic utility in ultrasound molecular imaging, MVT-601 is being evaluated for its potential in targeted drug delivery and the treatment of macular degeneration.

Other names: E-selectin targeted microbubbleE-selection targeted microbubble

Targets

SELP (P-selectin)SELE (E-selectin)

Beyond the preview

Go deeper on MVT-601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVT-601.

Explore the full profile